Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.53% during the night session on Wednesday, marking a significant upward movement for the biopharmaceutical company.

The surge appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.

Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.